RAMM Pharma Corp.
RAMM
CNSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.71M | 2.95M | 3.19M | 3.19M | 3.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.71M | 2.95M | 3.19M | 3.19M | 3.29M |
| Cost of Revenue | 2.06M | 1.85M | 1.92M | 1.89M | 2.89M |
| Gross Profit | 646.10K | 1.10M | 1.28M | 1.30M | 401.80K |
| SG&A Expenses | 6.12M | 6.62M | 7.52M | 7.78M | 5.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 83.70K | 84.90K | 86.30K | 89.10K | 95.40K |
| Total Operating Expenses | 8.27M | 8.56M | 9.53M | 9.76M | 8.31M |
| Operating Income | -5.56M | -5.61M | -6.33M | -6.56M | -5.03M |
| Income Before Tax | -9.65M | -9.99M | -11.19M | -12.10M | -6.53M |
| Income Tax Expenses | 9.10K | 9.10K | -56.90K | 5.90K | 7.10K |
| Earnings from Continuing Operations | -9.66 | -10.00 | -11.13 | -12.11 | -6.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.66M | -10.00M | -11.13M | -12.11M | -6.54M |
| EBIT | -5.56M | -5.61M | -6.33M | -6.56M | -5.03M |
| EBITDA | -5.04M | -4.97M | -5.58M | -5.72M | -4.23M |
| EPS Basic | -0.08 | -0.08 | -0.09 | -0.10 | -0.05 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| EPS Diluted | -0.08 | -0.08 | -0.09 | -0.10 | -0.05 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 477.56M | 477.56M | 477.56M | 477.56M | 477.53M |
| Average Diluted Shares Outstanding | 477.56M | 477.56M | 477.56M | 477.56M | 477.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |